Last reviewed · How we verify
Synergy for P. Aeruginosa Infection in Cystic Fibrosis
Approved treatments
- Ramycin
Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins. - Tobi · Novartis
- Vantobra · Pfizer
- Nebcin · University Hospital, Lille
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Synergy for P. Aeruginosa Infection in Cystic Fibrosis patent landscape — cliff calendar, originator estates, attackable patents
- Synergy for P. Aeruginosa Infection in Cystic Fibrosis treatment landscape brief
- Synergy for P. Aeruginosa Infection in Cystic Fibrosis treatment updates RSS
Frequently asked questions about Synergy for P. Aeruginosa Infection in Cystic Fibrosis
What drugs treat Synergy for P. Aeruginosa Infection in Cystic Fibrosis?
Tracked treatments include Ramycin, Tobi, Vantobra, Nebcin.
What is the treatment for Synergy for P. Aeruginosa Infection in Cystic Fibrosis?
Standard treatment for Synergy for P. Aeruginosa Infection in Cystic Fibrosis includes Ramycin, Tobi, Vantobra, Nebcin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Synergy for P. Aeruginosa Infection in Cystic Fibrosis patent cliff · Synergy for P. Aeruginosa Infection in Cystic Fibrosis CI report
- Treatment: Ramycin
- Treatment: Tobi · Novartis
- Treatment: Vantobra · Pfizer
- Treatment: Nebcin · University Hospital, Lille
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing